EpiCept to Hold Conference Call on March 1, 2007 to Provide Update on Oncology Program

TARRYTOWN, N.Y., Feb. 27 /PRNewswire-FirstCall/ -- EpiCept Corporation (Nasdaq and OMX Stockholm: EPCT) today announced that it will host a conference call on March 1, 2007 beginning at 8:30 a.m. Eastern time to discuss recent progress with its oncology programs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )

During the call EpiCept will provide an update on the regulatory progress of Ceplene(TM) (histamine dihydrochloride), its lead oncology product candidate that is administered in conjunction with low dose interleukin-2 (IL- 2) and is intended for use in the maintenance of first remission in patients with Acute Myeloid Leukemia (AML). A Marketing Authorization Application (MAA) for Ceplene is currently undergoing review by the European Medicines Agency for the Evaluation of Medicinal Products (EMEA).

EpiCept also will provide clinical and regulatory updates on its apoptosis program, including EPC2407, its novel small molecule vascular disruption agent and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas, as well as Azixa(TM), the lead compound in a series of apoptosis inducer compounds for the treatment of cancer. Azixa was licensed to Myriad Genetics, Inc. as part of an exclusive, worldwide development and commercialization agreement.

The conference call will be held Thursday, March 1, 2007 at 8:30 a.m. Eastern time. To participate in the live call, please dial [phone] from the U.S. or Canada or [phone] from international locations (please reference access code 8503894). The conference call will also be broadcast live on the Internet and may be accessed at http://www.epicept.com/. The webcast will be archived for 90 days.

A telephone replay of the call will be available for seven days by dialing [phone] from the U.S. and Canada or [phone] from international locations (please reference reservation number 8503894).

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that EpiCept will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; risks associated with our ability to maintain our listing on The Nasdaq Capital Market and our ability to receive stockholder approval for the Private Placement and SEDA; risks associated with our ability to have our common stock readmitted to trading on The Nasdaq Global Market; risks associated with the material weaknesses in our internal controls and the outcome of our SOX 404 audit; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in EpiCept's filings which are available at http://www.sec.gov/ or at http://www.epicept.com/. You are cautioned not to place undue reliance on any forward- looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.

EPCT-GEN
Photo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO